FR13C0013I2 - Analogues de peptide 2 du type glucagon - Google Patents

Analogues de peptide 2 du type glucagon

Info

Publication number
FR13C0013I2
FR13C0013I2 FR13C0013C FR13C0013C FR13C0013I2 FR 13C0013 I2 FR13C0013 I2 FR 13C0013I2 FR 13C0013 C FR13C0013 C FR 13C0013C FR 13C0013 C FR13C0013 C FR 13C0013C FR 13C0013 I2 FR13C0013 I2 FR 13C0013I2
Authority
FR
France
Prior art keywords
glucagon
analogs
type peptide
peptide
synthesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR13C0013C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
1506385 Alberta Ltd
Shire NPS Pharmaceuticals Inc
Original Assignee
1506385 Alberta Ltd
NPS Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24530501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR13C0013(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 1506385 Alberta Ltd, NPS Pharmaceuticals Inc filed Critical 1506385 Alberta Ltd
Publication of FR13C0013I1 publication Critical patent/FR13C0013I1/fr
Application granted granted Critical
Publication of FR13C0013I2 publication Critical patent/FR13C0013I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
FR13C0013C 1996-04-12 2013-02-22 Analogues de peptide 2 du type glucagon Active FR13C0013I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63127396A 1996-04-12 1996-04-12
PCT/CA1997/000252 WO1997039031A1 (en) 1996-04-12 1997-04-11 Glucagon-like peptide-2 analogs

Publications (2)

Publication Number Publication Date
FR13C0013I1 FR13C0013I1 (de) 2013-05-04
FR13C0013I2 true FR13C0013I2 (fr) 2013-08-16

Family

ID=24530501

Family Applications (1)

Application Number Title Priority Date Filing Date
FR13C0013C Active FR13C0013I2 (fr) 1996-04-12 2013-02-22 Analogues de peptide 2 du type glucagon

Country Status (16)

Country Link
EP (5) EP2009024A1 (de)
JP (3) JP4148994B2 (de)
CN (1) CN1268640C (de)
AT (2) ATE227309T1 (de)
AU (1) AU733857B2 (de)
BR (1) BRPI9708566B8 (de)
CA (1) CA2251576C (de)
DE (2) DE69716905T2 (de)
DK (2) DK0906338T3 (de)
ES (2) ES2351661T3 (de)
FR (1) FR13C0013I2 (de)
HK (3) HK1033324A1 (de)
LU (1) LU92153I2 (de)
NZ (1) NZ332281A (de)
PT (2) PT906338E (de)
WO (1) WO1997039031A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
AU733857B2 (en) * 1996-04-12 2001-05-31 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US5952301A (en) * 1996-12-10 1999-09-14 1149336 Ontario Inc. Compositions and methods for enhancing intestinal function
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
DK0981362T3 (da) * 1997-05-16 2004-03-15 Ontario Inc 1149336 Anvendelse af GLP-2-agonister, der forbedrer funktionen af den øvre mavetarmkanal
WO1999043361A1 (en) * 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
WO1999058144A1 (en) * 1998-05-11 1999-11-18 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
WO2002022151A2 (en) 2000-09-18 2002-03-21 Osteometer Bio Tech A/S Use of glp-1 and flp-2 peptides for treatment of bone disorders
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
WO2004035624A2 (en) * 2002-10-14 2004-04-29 Novo Nordisk A/S Glucagon - like peptide - 2 variants
EP1592471B1 (de) 2003-02-04 2011-03-23 Novo Nordisk A/S Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
EP1664109B1 (de) * 2003-08-21 2009-07-22 Novo Nordisk A/S Reinigung glucagonähnlicher peptide
ATE550041T1 (de) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag Transglutaminase-vermittelte konjugation von peptiden
EP1809318B1 (de) * 2004-11-01 2013-06-12 NPS Pharmaceuticals, Inc. Behandlung von patienten mit kurzdarmsyndrom und dickdarmkontinuität
BRPI0610091B1 (pt) 2005-05-04 2021-08-03 Zealand Pharma A/S Análogo de peptídeo 2 tipo glucagon (glp-2), composição farmacêutica, uso de um análogo de glp-2, e, kit terapêutico
CN100418983C (zh) * 2005-05-11 2008-09-17 中国药科大学 人胰高血糖素相关肽-2类似物
CN101573376B (zh) 2006-11-08 2013-11-06 西兰制药公司 选择性胰高血糖素样肽-2（glp-2）类似物
CN102942626B (zh) * 2009-03-05 2015-11-04 江苏豪森医药集团有限公司 胰高血糖素样肽-2类似物及其制备方法和用途
EP2311486A1 (de) * 2009-10-07 2011-04-20 Nestec S.A. GLP-2 zur Verwendung in der Dünndarm- und Muskelwiederherstellung
EP2314616A1 (de) * 2009-10-23 2011-04-27 Ferring B.V. GLP-2-Peptid-Agonisten
BR112012011467A2 (pt) * 2009-10-30 2019-09-24 Otsuka Chemical Co Ltd forma glicosilada de análogo ao glp-1 antigênico.
US9782454B2 (en) 2010-04-22 2017-10-10 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
EP2569001A4 (de) * 2010-05-11 2014-06-25 Nps Pharma Inc Verfahren zur behandlung von oder vorbeugung gegen nieren- oder leberfehlfunktionen
EP2694083A2 (de) 2011-04-01 2014-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Peptide und pharmazeutische zusammensetzungen zur nasalen verabreichung für die behandlung von patienten mit angstzuständen und schlafstörungen
CN102924589B (zh) * 2011-08-11 2016-08-24 中肽生化有限公司 胰高血糖素样肽-2(glp-2)的类似物及其制备方法和用途
TR201802689T4 (tr) 2012-05-03 2018-03-21 Zealand Pharma As Glukagon benzeri peptit-2 (glp-2) analogları.
CN103159848B (zh) * 2013-01-06 2015-11-25 中国人民解放军第四军医大学 人胰高血糖素样肽-2二串体蛋白及其制备方法
US9789164B2 (en) 2013-03-15 2017-10-17 Longevity Biotech, Inc. Peptides comprising non-natural amino acids and methods of making and using the same
US10774127B2 (en) * 2016-10-12 2020-09-15 University Of Copenhagen Peptide dual agonists of GIPR and GLP2R
JP6563614B1 (ja) 2016-12-09 2019-08-21 ジーランド・ファーマ・ア／エス アシル化ｇｌｐ−１／ｇｌｐ−２二重アゴニスト
WO2019086559A1 (fr) 2017-10-31 2019-05-09 Adocia Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2020020904A1 (en) 2018-07-23 2020-01-30 Zealand Pharma A/S Therapeutic uses of glp-2 agonists
EP3628682A1 (de) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
EP3628683A1 (de) 2018-09-28 2020-04-01 Zealand Pharma A/S Formulierungen von analoga des glucagon-like-peptid-2 (glp-2)
KR20210126088A (ko) 2019-02-11 2021-10-19 옵코 바이오로직스 리미티드 지속성 glp-2 유사체
WO2021071837A1 (en) 2019-10-07 2021-04-15 Kallyope, Inc. Gpr119 agonists
EP4126004A1 (de) 2020-03-30 2023-02-08 Zealand Pharma A/S Agonistenkombination
WO2023111273A1 (en) * 2021-12-17 2023-06-22 Bainan Biotech Aps Peptide dual agonists of gipr and glp2r

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5186117A (en) 1975-01-27 1976-07-28 Tanabe Seiyaku Co Johoseibiryushiseizainoseiho
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4529561A (en) 1978-03-24 1985-07-16 The Regents Of The University Of California Method for producing liposomes in selected size range
GB2046092B (en) 1979-03-05 1983-11-02 Toyama Chemical Co Ltd Pharmaceutical composition containing a lysophospholid and a phospholipid
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US5008050A (en) 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4921706A (en) 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4920016A (en) 1986-12-24 1990-04-24 Linear Technology, Inc. Liposomes with enhanced circulation time
US5009956A (en) 1987-02-24 1991-04-23 Univ Minnesota Phospholipase A2-resistant liposomes
US4927637A (en) 1989-01-17 1990-05-22 Liposome Technology, Inc. Liposome extrusion method
US4944948A (en) 1989-02-24 1990-07-31 Liposome Technology, Inc. EGF/Liposome gel composition and method
JP2961045B2 (ja) * 1993-02-24 1999-10-12 日清製粉株式会社 腸管粘膜増強促進剤
EP0658568A1 (de) 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-ähnliche, insalinotrope Peptide, ihre Zusammensetzungen und ihre Herstellungsverfahren
US5990077A (en) 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
AU710818B2 (en) 1996-03-01 1999-09-30 Novo Nordisk A/S Use of a pharmaceutical composition comprising an appetite-suppressing peptide
AU733857B2 (en) 1996-04-12 2001-05-31 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US5994500A (en) 1996-07-19 1999-11-30 1149336 Ontario Inc. Antagonists of intestinotrophic GLP-2 peptides
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity

Also Published As

Publication number Publication date
AU733857B2 (en) 2001-05-31
JP2000511881A (ja) 2000-09-12
ATE227309T1 (de) 2002-11-15
EP1231219A1 (de) 2002-08-14
HK1050204A1 (en) 2003-06-13
EP1231219B1 (de) 2010-08-25
BRPI9708566A (pt) 2000-01-04
PT906338E (pt) 2003-03-31
HK1147761A1 (en) 2011-08-19
NZ332281A (en) 2000-03-27
ES2351661T3 (es) 2011-02-09
JP4148994B2 (ja) 2008-09-10
JP2008184465A (ja) 2008-08-14
PT1231219E (pt) 2010-11-30
BRPI9708566B8 (pt) 2022-01-18
EP2218734B1 (de) 2013-06-05
JP2007204491A (ja) 2007-08-16
EP2275438A1 (de) 2011-01-19
ATE478892T1 (de) 2010-09-15
CA2251576A1 (en) 1997-10-23
HK1033324A1 (en) 2001-08-24
WO1997039031A1 (en) 1997-10-23
EP2218734A3 (de) 2010-10-13
CA2251576C (en) 2012-08-21
LU92153I2 (fr) 2013-04-19
DK1231219T3 (da) 2010-12-20
DE69716905D1 (de) 2002-12-12
JP5019466B2 (ja) 2012-09-05
DK0906338T3 (da) 2003-03-03
DE60142885D1 (de) 2010-10-07
FR13C0013I1 (de) 2013-05-04
BR9708566B1 (pt) 2012-09-04
DE69716905T2 (de) 2003-07-24
CN1244872A (zh) 2000-02-16
ES2188929T3 (es) 2003-07-01
EP0906338B1 (de) 2002-11-06
HK1050204B (zh) 2011-09-23
CN1268640C (zh) 2006-08-09
AU2500297A (en) 1997-11-07
EP0906338A1 (de) 1999-04-07
JP4149497B2 (ja) 2008-09-10
EP2218734A2 (de) 2010-08-18
EP2009024A1 (de) 2008-12-31

Similar Documents

Publication Publication Date Title
FR13C0013I2 (fr) Analogues de peptide 2 du type glucagon
HUP0100928A2 (hu) Humán inzulin B láncának részletét tartalmazó peptidanalógok, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
HUT64298A (en) Method for producing 9-amino-7-(substituted)-6-demethyl-6-desoxy-0tetracycline derivatives and medical preparatives containing them
ATE259420T1 (de) Mutanten des keratinocyten-wachstumsfaktor-2 (kgf-2 oder fibroblastenwachstumsfaktor-12,fgf-12)
DK0833646T3 (da) Multi-tyrosinerede somatostatinanaloger
ATE245435T1 (de) Totalsynthese des amino hip analogen von didemnin a
SE9903291D0 (sv) New process
ATE236139T1 (de) Verfahren zur herstellung von 2-chlor-5- chlomethyl-thiazol-derivaten
GR3018096T3 (en) Polypeptide comprising repeated cell-adhesive core sequences.
ES2196088T3 (es) Analogos del factor de crecimiento de los queratinocitos.
IL112098A0 (en) Sulfamate derivatives and pharmaceutical compositions containing them
IL91317A0 (en) New antibiotic,mersacidin,a process for the preparation thereof and the use thereof as a pharmaceutical
NO175745C (no) Analogifremgangsmåte for fremstilling av dibenzo(1,5)-dioksocin-5-oner
ATE308533T1 (de) Zwischenprodukt und verfahren zur teilsynthese von paclitaxel und dessen analogen
DE59610819D1 (de) Arzneistoffe zur selektiven bekämpfung von tumorgewebe
EP0603399A4 (en) Endothelin-antagonizing peptide.
SE9800865D0 (sv) New Process
ATE121726T1 (de) Hydroquinonester von aminosäuren, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische oder kosmetische zusammensetzungen.
MX9602804A (es) Derivados del 3-aril-alquenil-1,2,4-oxadiazol y su uso como parasiticidas para animales.
ES2049186A1 (es) Procedimiento para la preparacion de nuevos derivados de benzofuranil-imidazol.
AP1734A (en) Crystalline forms of 1S-[1alpha(2S*,3*), 9 alpha]-6, 10-dioxo-N-(2-ethoxy-5- oxo-tetrahydro-3-furanyl)-9-[[(isoquinolyl) carbonyl]-amino] octahydro-6H-piridazino[1,2-A][1,2] diazepin- 1-carboxamide.
FR2678949B1 (fr) Procede d'obtention d'un complexe proteique d'action stabilisatrice de la degenerescence.
ZA911397B (en) N-cycloalkylalkylamines,their process of preparation,their use as a medicament and their synthesis intermediates
MX9704796A (es) Peptidos novedosos, su preparacion y uso.